NSE · ARISTO
Aristo Bio-Tech & Lifescience Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹364 Cr with net profit ₹7 Cr — a 1.97% net margin, versus 1.28% the period before.
Shareholding
As of 2026-03-31
- Promoter73.42%
- Public26.58%
453 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.85× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pesticides / Agrochemicals - Indian · ranked #1 of 29 by market cap · medians across 27 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| UPL Limited | ₹47,250 Cr | 23.88 | 1.36 | 5.54% | 3.83% |
| PI Industries Ltd. | ₹36,564 Cr | 33.85 | 3.25 | 11.76% | 17.88% |
| Sumitomo Chemical India Ltd. | ₹22,836 Cr | 39.96 | 6.73 | 16.02% | 17.86% |
| Sharda Cropchem Ltd. | ₹6,743 Cr | 10.77 | 2.15 | 21.71% | 11.69% |
| Dhanuka Agritech Ltd. | ₹4,308 Cr | 14.76 | 3.07 | 21.17% | 14.59% |
| Rallis India Ltd. | ₹3,927 Cr | 17.2 | 1.92 | 9.88% | 7.22% |
| NACL Industries Limited | ₹3,247 Cr | 124.88 | 4.76 | 2.49% | 0.81% |
| Bhagiradha Chemicals & Industries Ltd. | ₹3,162 Cr | 115.02 | 4.53 | 2.6% | 4.53% |
| Bharat Rasayan Ltd. | ₹1,877 Cr | 12.84 | 1.47 | 11.43% | 11.92% |
| Insecticides India Ltd. | ₹1,780 Cr | 14.22 | 1.46 | 11.42% | 6.08% |
| Aristo Bio-Tech & Lifescience Ltd.(this company) | — | 10.62 | 1.71 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashAristo Bio-Tech & Lifescience Ltd. has a market capitalization of Rs 61 Cr. The company reported revenue of Rs 318.55 Cr and an EPS of 10.55. Its debt-to-equity ratio stands at 0.6. The promoter holding is 73.4187%.
Positives
- +The promoter holding is substantial at 73.4187% as of March 31, 2026.
- +The company's revenue increased from Rs 245.3283 Cr in March 2024 to Rs 318.5463 Cr in March 2025.
- +The net profit increased from Rs 3.8957 Cr in March 2024 to Rs 4.0631 Cr in March 2025.
Negatives
- −No Return on Equity (ROE) figure has been disclosed.
- −No quarterly results have been disclosed in the provided data.
- −No dividend yield figure has been disclosed.
- −No information on revenue growth rate for the latest period is provided.
Financial Performance
The company's annual revenue has shown growth, increasing from Rs 245.3283 Cr in March 2024 to Rs 318.5463 Cr in March 2025. Net profit also rose from Rs 3.8957 Cr in March 2024 to Rs 4.0631 Cr in March 2025. Earnings per share increased from Rs 5.72 in March 2024 to Rs 5.97 in March 2025. EBITDA saw a slight increase from Rs 7.1018 Cr in March 2024 to Rs 7.1246 Cr in March 2025.
Profitability & Returns
Aristo Bio-Tech & Lifescience Ltd. reported a Return on Capital Employed (ROCE) of 12.53%. The Earnings Per Share (EPS) for the latest period is 10.55. The Price-to-Earnings (PE) ratio for the company is 10.9. No Return on Equity (ROE) figure has been disclosed.
Balance Sheet
The company maintains a debt-to-equity ratio of 0.6. Its book value is reported at Rs 65.39. Further details regarding assets, liabilities, or specific components of debt are not provided in the available data.
Ownership & Pledges
Public shareholding is 26.5813%. There is no promoter pledge reported as of March 31, 2026. The number of shareholders as of March 31, 2026, is 453. Neither DII nor FII holding is reported for this period.
Regulatory & Surveillance
No information regarding the company being under surveillance by regulatory bodies has been disclosed in the provided data. There are no reported pledges by promoters for any period.
Data as of — price: 2026-09-23 · financials: Mar 26 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Aristo Bio-Tech & Lifescience Ltd.share price & fundamentals